262 related articles for article (PubMed ID: 31251436)
1. Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.
Mullin S; Beavan M; Bestwick J; McNeill A; Proukakis C; Cox T; Hughes D; Mehta A; Zetterberg H; Schapira AHV
Mov Disord; 2019 Sep; 34(9):1365-1373. PubMed ID: 31251436
[TBL] [Abstract][Full Text] [Related]
2. Evolution of prodromal parkinsonian features in a cohort of
Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
[TBL] [Abstract][Full Text] [Related]
3. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest Risk.
Becker-Cohen M; Zimran A; Dinur T; Tiomkin M; Cozma C; Rolfs A; Arkadir D; Shulman E; Manor O; Paltiel O; Yahalom G; Berg D; Revel-Vilk S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293067
[TBL] [Abstract][Full Text] [Related]
5. Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder.
Barber TR; Lawton M; Rolinski M; Evetts S; Baig F; Ruffmann C; Gornall A; Klein JC; Lo C; Dennis G; Bandmann O; Quinnell T; Zaiwalla Z; Ben-Shlomo Y; Hu MTM
Sleep; 2017 Aug; 40(8):. PubMed ID: 28472425
[TBL] [Abstract][Full Text] [Related]
6. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
[TBL] [Abstract][Full Text] [Related]
7. Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.
Arkadir D; Dinur T; Becker Cohen M; Revel-Vilk S; Tiomkin M; Brüggemann N; Cozma C; Rolfs A; Zimran A
Eur J Neurol; 2019 Jul; 26(7):1013-1018. PubMed ID: 30714262
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal evaluation of olfactory function in individuals with Gaucher disease and
Lopez GJ; Lichtenberg J; Tayebi N; Ryan E; Lecker AL; Sidransky E
Front Neurol; 2022; 13():1039214. PubMed ID: 36330429
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
10. The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease.
Higgins AL; Toffoli M; Mullin S; Lee CY; Koletsi S; Avenali M; Blandini F; Schapira AH
Neurodegener Dis Manag; 2021 Dec; 11(6):451-458. PubMed ID: 34666501
[TBL] [Abstract][Full Text] [Related]
11. Hyposmia and cognitive impairment in Gaucher disease patients and carriers.
McNeill A; Duran R; Proukakis C; Bras J; Hughes D; Mehta A; Hardy J; Wood NW; Schapira AH
Mov Disord; 2012 Apr; 27(4):526-32. PubMed ID: 22344629
[TBL] [Abstract][Full Text] [Related]
12. Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.
Menozzi E; Schapira AHV; Blandini F; Avenali M
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):121-130. PubMed ID: 36881256
[TBL] [Abstract][Full Text] [Related]
13. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of sibling pairs with gaucher disease discordant for parkinsonism.
Lopez G; Steward A; Ryan E; Groden C; Wiggs E; Segalà L; Monestime GM; Tayebi N; Sidransky E
Mov Disord; 2020 Feb; 35(2):359-365. PubMed ID: 31785030
[TBL] [Abstract][Full Text] [Related]
15. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
Filippi M; Balestrino R; Basaia S; Agosta F
Mov Disord; 2022 Jul; 37(7):1375-1393. PubMed ID: 35521899
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
18. PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
Noyce AJ; R'Bibo L; Peress L; Bestwick JP; Adams-Carr KL; Mencacci NE; Hawkes CH; Masters JM; Wood N; Hardy J; Giovannoni G; Lees AJ; Schrag A
Mov Disord; 2017 Feb; 32(2):219-226. PubMed ID: 28090684
[TBL] [Abstract][Full Text] [Related]
19. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
Blauwendraat C; Tayebi N; Woo EG; Lopez G; Fierro L; Toffoli M; Limbachiya N; Hughes D; Pitz V; Patel D; Vitale D; Koretsky MJ; Hernandez D; Real R; Alcalay RN; Nalls MA; Morris HR; Schapira AHV; Balwani M; Sidransky E
Mov Disord; 2023 May; 38(5):899-903. PubMed ID: 36869417
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase and its relevance to Parkinson disease.
Do J; McKinney C; Sharma P; Sidransky E
Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
